Lichen sclerosus is a chronic inflammatory skin condition, and while it's understandable to look for procedures that may improve symptoms, it's important to know that vaginal rejuvenation procedures are not considered first-line treatment for this condition. The treatment with the strongest medical evidence remains high-potency topical corticosteroids, such as clobetasol ointment. These medications help reduce inflammation, relieve itching, minimize scarring, and lower the risk of long-term complications. Many women also benefit from regular use of moisturizers or barrier ointments to help protect the delicate vulvar skin. Regarding Morpheus8 V, there is currently limited scientific evidence supporting its use specifically for lichen sclerosus. While radiofrequency microneedling is designed to stimulate collagen remodeling and improve tissue quality, lichen sclerosus is an autoimmune inflammatory disorder rather than simply an issue of aging or skin laxity. For that reason, Morpheus8 V should not replace established medical therapy. Some energy-based devices—including fractional CO₂ lasers and radiofrequency treatments—have shown promising early results in small studies for selected patients with persistent symptoms. However, the available research is still limited, and these procedures are generally considered adjunctive or investigational rather than standard treatment. More long-term studies are needed to determine their safety and effectiveness in managing lichen sclerosus. Because you are 53 years old and three years into menopause, it's also possible that genitourinary syndrome of menopause (GSM) is contributing to symptoms such as dryness, irritation, discomfort, or painful intercourse. In some women, treating menopausal changes with localized vaginal estrogen (when appropriate) can significantly improve tissue health, although it does not treat the underlying lichen sclerosus itself. If your lichen sclerosus is well controlled with medical therapy but you're interested in improving tissue quality or symptoms that persist despite treatment, discussing energy-based procedures with a clinician who has specific experience managing vulvar disorders may be worthwhile. The key is to ensure the underlying inflammation is controlled first before considering any procedural intervention. Overall, I would not consider Morpheus8 V the primary treatment for lichen sclerosus. The best outcomes are generally achieved by controlling the disease with proven medical therapy first, then considering carefully selected adjunctive treatments if symptoms remain despite appropriate management.